Technological development frontier and future trend of cardiovascular surgery_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

SHANG Xiaoke , ZHANG Changdong , ZHONG Yucheng ,  DONG Nianguo

Department of Cardiovascular Surgery, Huazhong University of Science and Technology, Union Hospital Affiliated Tongji Medical College, Wuhan, 430022, P. R. China;

Corresponding author：

DONG Nianguo, Email: sxs_dng@163.com

Keywords：

Lifelong management; new artificial heart valve prosthesis; valve-in-valve; septal myectomy; cardiac structural intervention; extended standard donors; ventricular assist device; review

DOI：

10.7507/1007-4848.202408005

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, the field of cardiovascular surgery has undergone revolutionary changes and made rapid progress in various aspects, bringing more hope and possibilities for the health and well-being of patients. The constant emergence of new technologies brings new opportunities and hope, as well as constant challenges to past concepts. This article aims to provide a comprehensive overview of the latest developments in cardiovascular surgery in recent years, especially since 2023. It introduces cutting-edge knowledge and technologies in the field of cardiovascular surgery, including lifelong management of aortic valve disease, artificial valves, mitral valves, treatment options for hypertrophic obstructive cardiomyopathy, heart transplantation, left ventricular assist, coronary artery surgery, cardiac structural interventions for chronic heart failure, aortic dissection, and comprehensive surgical treatment of atrial fibrillation. It also analyzes and explores future development directions in depth, aiming to provide useful references and inspiration for cardiovascular doctors and jointly promote the continuous progress of cardiovascular surgery in China.

Citation： SHANG Xiaoke, ZHANG Changdong, ZHONG Yucheng, DONG Nianguo. Technological development frontier and future trend of cardiovascular surgery. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2025, 32(1): 41-53. doi: 10.7507/1007-4848.202408005 Copy

1.	Lee G, Chikwe J, Milojevic M, et al. ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Eur Heart J, 2023, 44(10): 796-812.
2.	Blankenberg S, Seiffert M, Vonthein R, et al. Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med, 2024, 390(17): 1572-1583.
3.	Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J, 2024, 45(13): 1116-1124.
4.	Elbasha K, Kaur J, Abdelghani M, et al. Ten-year durability, hemodynamic performance, and clinical outcomes after transcatheter aortic valve implantation using a self-expanding device. Cardiol Ther, 2024, 13(3): 529-540.
5.	Tarantini G, Dvir D, Tang GHL. Transcatheter aortic valve implantation in degenerated surgical aortic valves. EuroIntervention, 2021, 17(9): 709-719.
6.	Mehta CK, Liu TX, Bonnell L, et al. Age-stratified surgical aortic valve replacement for aortic stenosis. Ann Thorac Surg, 2024, 118(2): 430-438.
7.	Sharma T, Krishnan AM, Lahoud R, et al. National trends in TAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol, 2022, 80(21): 2054-2056.
8.	Basman C, Pirelli L, Singh VP, et al. Lifetime management for aortic stenosis: Planning for future therapies. J Cardiol, 2022, 80(3): 185-189.
9.	Russo G, Tang GHL, Sangiorgi G, et al. Lifetime management of aortic stenosis: Transcatheter versus surgical treatment for young and low-risk patients. Circ Cardiovasc Interv, 2022, 15(11): 915-927.
10.	Baman JR, Medhekar AN, Malaisrie SC, et al. Management challenges in patients younger than 65 years with severe aortic valve disease: A review. JAMA Cardiol, 2023, 8(3): 281-289.
11.	Mylonas KS, Angouras DC. Bioprosthetic valves for lifetime management of aortic stenosis: Pearls and pitfalls. J Clin Med, 2023, 12(22): 7063.
12.	Geuens L, Van Hoof L, Van De Bruaene A, et al. Aortic valve replacement in non-elderly: The gap between reality, guidelines and evidence. Eur J Cardiothorac Surg, 2023, 64(5): ezad318.
13.	Jubran A, Patel RV, Sathananthan J, et al. Lifetime management of patients with severe aortic stenosis in the era of transcatheter aortic valve replacement. Can J Cardiol, 2024, 40(2): 210-217.
14.	Matsushita K, Morel O, Ohlmann P. Contemporary issues and lifetime management in patients underwent transcatheter aortic valve replacement. Cardiovasc Interv Ther, 2023, 38(3): 275-286.
15.	Medranda GA, Soria Jimenez CE, Torguson R, et al. Lifetime management of patients with symptomatic severe aortic stenosis: A computed tomography simulation study. EuroIntervention, 2022, 18(5): e407-e416.
16.	De Backer O, Søndergaard L. Discussing lifetime management of patients with severe aortic valve stenosis should be standard at heart team meetings. JACC Cardiovasc Interv, 2022, 15(7): 709-711.
17.	Sá MP, Ramlawi B, Sicouri S, et al. Lifetime management of aortic valve disease: Aligning surgical and transcatheter armamentarium to set the tone for the present and the future. J Card Surg, 2022, 37(1): 205-213.
18.	Reul RM, Nissen AP, Tom SK, et al. Incorporating redo-TAVR feasibility into lifelong aortic valve management. Circ Cardiovasc Interv, 2023, 16(11): e013571.
19.	Prendergast BP, Patterson T. New paradigms for the sequential treatment of severe aortic stenosis: Imaging-guided selection of the first intervention paves the way for lifetime management. EuroIntervention, 2022, 18(5): e357-e359.
20.	Tully A, Tom S, Crepy D'Orleans C, et al. Advancing transcatheter aortic valve replacement to the frontiers of lifetime valve management: Deliberations from the OBSERVANTⅡ trial. Circ Cardiovasc Interv, 2022, 15(12): e012607.
21.	Sharaf OM, Beaver TM. Aortic valve 2024: Which valve for which patient? J Thorac Cardiovasc Surg, 2024: S0022-5223.
22.	Leone PP, Regazzoli D, Pagnesi M, et al. Implantation of contemporary transcatheter aortic valves in small aortic annuli: The international multicentre TAVI-SMALL 2 registry. EuroIntervention, 2023, 19(3): 256-266.
23.	Rao V, Linick JA, Reardon MJ, et al. Early and late effects of aortic root enlargement: Results from the pericardial surgical aortic valve replacement pivotal trial: A multicenter, prospective clinical trial. JTCVS Open, 2022, 13: 54-74.
24.	Yang B. Aortic annular enlargement with Y-incision/rectangular patch. Ann Cardiothorac Surg, 2024, 13(3): 294-302.
25.	Sá MPBO, Van den Eynde J, Simonato M, et al. Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement: An updated meta-analysis. JACC Cardiovasc Interv, 2021, 14(2): 211-220.
26.	Woitek FJ, Stachel G, Kiefer P, et al. Treatment of failed aortic bioprostheses: An evaluation of conventional redo surgery and transfemoral transcatheter aortic valve-in-valve implantation. Int J Cardiol, 2020, 300: 80-86.
27.	Bagga S, Chhatriwalla AK. Updates on bioprosthetic valve fracture. Expert Rev Cardiovasc Ther, 2023, 21(6): 409-422.
28.	Ochiai T, Oakley L, Sekhon N, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2020, 13(22): 2617-2627.
29.	Kitamura M, Wilde J, Dumpies O, et al. Risk assessment of coronary obstruction during transcatheter aortic valve replacement: Insights from post-BASILICA computed tomography. JACC Cardiovasc Interv, 2022, 15(5): 496-507.
30.	Babaliaros VC, Gleason PT, Xie JX, et al. Toward transcatheter leaflet removal with the CATHEDRAL procedure: CATHeter Electrosurgical Debulking and RemovAL. JACC Cardiovasc Interv, 2022, 15(16): 1678-1680.
31.	Vilalta V, Asmarats L, Ferreira-Neto AN, et al. Incidence, clinical characteristics, and impact of acute coronary syndrome following transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2018, 11(24): 2523-2533.
32.	Barbanti M, Costa G, Picci A, et al. Coronary cannulation after transcatheter aortic valve replacement: The RE-ACCESS study. JACC Cardiovasc Interv, 2020, 13(21): 2542-2555.
33.	Tang GHL, Zaid S. Commissural (mis)alignment in TAVR and hemodynamic impact: More questions raised than answered. JACC Cardiovasc Interv, 2022, 15(11): 1137-1139.
34.	Giuliani C, Zanuttini A, Salaun E, et al. Subclinical valve leaflet thrombosis following bioprosthetic aortic valve replacement. Curr Opin Cardiol, 2024, 39(5): 457-464.
35.	Mauri V, Körber MI, Kuhn E, et al. Prognosis of persistent mitral regurgitation in patients undergoing transcatheter aortic valve replacement. Clin Res Cardiol, 2020, 109(10): 1261-1270.
36.	Kang JJ, Fialka NM, El-Andari R, et al. Surgical vs transcatheter aortic valve replacement in bicuspid aortic valve stenosis: A systematic review and meta-analysis. Trends Cardiovasc Med, 2024, 34(5): 304-313.
37.	Sá MP, Van den Eynde J, Jacquemyn X, et al. Long-term outcomes of Ross procedure versus mechanical aortic valve replacement: Meta-analysis of reconstructed time-to-event data. Trends Cardiovasc Med, 2024, 34(1): 29-36.
38.	Shih E, Ryan WH, Squiers JJ, et al. Outcomes of the Ross procedure in patients older versus younger than 50 years old. Eur J Cardiothorac Surg, 2023, 64(4): ezad260.
39.	Pollari F, Mamdooh H, Hitzl W, et al. Ten years' experience with the sutureless aortic valve replacement: Incidence and predictors for survival and valve durability at follow-up. Eur J Cardiothorac Surg, 2023, 63(2): ezac572.
40.	Concistrè G, Bianchi G, Margaryan R, et al. Ten-year experience with sutureless Perceval bioprosthesis: Single-centre analysis in 1157 implants. J Cardiovasc Med (Hagerstown), 2023, 24(8): 506-513.
41.	Lamberigts M, Sarrazin B, Szecel D, et al. 15 years of experience with sutureless AVR: Long-term outcome in 1135 patients. USA, Massachusetts: HVS 2024 annual meeting.
42.	Bernard J, Georges G, Hecht S, et al. Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve: A retrospective comparison to the Magna Ease. Interdiscip Cardiovasc Thorac Surg, 2023, 37(1): ivad117.
43.	Bavaria JE, Griffith B, Heimansohn DA, et al. Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue. Ann Thorac Surg, 2023, 115(6): 1429-1436.
44.	Bartus K, Bavaria JE, Thourani VH, et al. Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses. J Comp Eff Res, 2023, 12(3): e220180.
45.	Sef D, Thet MS, Klokocovnik T, et al. Early and mid-term outcomes after aortic valve replacement using a novel tissue bioprosthesis: A systematic review. Eur J Cardiothorac Surg, 2024, 65(2): ezae045.
46.	Kereiakes DJ, Answini GA, Yakubov SJ, et al. Preliminary evaluation of a novel polymeric valve following surgical implantation for symptomatic aortic valve disease. JACC Cardiovasc Interv, 2021, 14(24): 2754-2756.
47.	Ge JB. Innovations in structural heart diseases from China. USA, California: TCT, 2023.
48.	Carrel T, Vogt PR, Obrist D, et al. Evolving technology: The TRIFLO tri-leaflet mechanical valve without oral anticoagulation: A potential major innovation in valve surgery. Front Cardiovasc Med, 2023, 10: 1220633.
49.	Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: A report from the STS/ACC TVT Registry. Ann Thorac Surg, 2022, 113(1): 337-365.
50.	Chikwe J, Chen Q, Bowdish ME, et al. Surgery and transcatheter intervention for degenerative mitral regurgitation in the United States. J Thorac Cardiovasc Surg, 2024.
51.	Xu X, Liu H, Gu J, et al. Valve-in-valve/valve-in-ring transcatheter mitral valve implantation vs. redo surgical mitral valve replacement for patients with failed bioprosthetic valves or annuloplasty rings: A systematic review and meta-analysis. Heliyon, 2023, 9(5): e16078.
52.	Ueyama HA, Miyamoto Y, Watanabe A, et al. Cardiac reoperation or transcatheter mitral valve replacement for patients with failed mitral prostheses. J Am Coll Cardiol, 2024, 83(2): 317-330.
53.	Simard T, Lloyd J, Crestanello J, et al. Five-year outcomes of transcatheter mitral valve implantation and redo surgery for mitral prosthesis degeneration. Catheter Cardiovasc Interv, 2022, 99(5): 1659-1665.
54.	Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults. Am J Med, 2004, 116(1): 14-18.
55.	Fang J, Liu Y, Zhu Y, et al. First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 2023, 82(7): 575-586.
56.	Li J, Wei X. Transapical beating-heart septal myectomy for hypertrophic cardiomyopathy with latent obstruction. Eur J Cardiothorac Surg, 2024, 65(1): ezad425.
57.	Schaff HV, Cui H. Septal myectomy: An evolving therapy for obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol, 2023, 82(7): 587-589.
58.	Quintana E, Schaff HV, Stradiņš P, et al. Beating heart transapical septal myectomy—A less invasive septal reduction option for hypertrophic cardiomyopathy. Eur J Cardiothorac Surg, 2024, 65(1): ezae003.
59.	Fang J, Liu Y, Wan S, et al. Reply: Potential expanded applications of minimally invasive cardiac myectomy. J Am Coll Cardiol, 2023, 82(24): e237.
60.	Pai RG. Potential Expanded applications of minimally invasive cardiac myectomy. J Am Coll Cardiol, 2023, 82(24): e235.
61.	Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2020 annual data report: Heart. Am J Transplant, 2022, 22 Suppl 2: 350-437.
62.	Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report—2019; focus theme: Donor and recipient size matchJ Heart Lung Transplant, 2019, 38(10): 1056-1066.
63.	Jou S, Mendez SR, Feinman J, et al. Heart transplantation: Advances in expanding the donor pool and xenotransplantation. Nat Rev Cardiol, 2024, 21(1): 25-36.
64.	Crespo-Leiro MG, Costanzo MR, Gustafsson F, et al. Heart transplantation: Focus on donor recovery strategies, left ventricular assist devices, and novel therapies. Eur Heart J, 2022, 43(23): 2237-2246.
65.	Kilic A, Hickey G, Mathier M, et al. Outcomes of adult heart transplantation using hepatitis C-positive donors. J Am Heart Assoc, 2020, 9(2): e014495.
66.	Aslam S, Grossi P, Schlendorf KH, et al. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant, 2020, 39(5): 418-432.
67.	Villegas-Galaviz J, Anderson E, Guglin M. Clinical outcomes of heart transplantation using hepatitis C-viremic donors: A systematic review with meta-analysis. J Heart Lung Transplant, 2022, 41(4): 538-549.
68.	Gidea CG, Narula N, Reyentovich A, et al. Increased early acute cellular rejection events in hepatitis C-positive heart transplantation. J Heart Lung Transplant, 2020, 39(11): 1199-1207.
69.	Madan S, Saeed O, Forest SJ, et al. Feasibility and potential impact of heart transplantation from adult donors after circulatory death. J Am Coll Cardiol, 2022, 79(2): 148-162.
70.	Louca J, Öchsner M, Shah A, et al. The international experience of in-situ recovery of the DCD heart: A multicentre retrospective observational study. EClinicalMedicine, 2023, 58: 101887.
71.	Schroder J, Shah A, Pretorius V, et al. Expanding heart transplants from donors after Circulatory Death (DCD)—Results of the first randomized controlled trial using the Organ Care System (OCS™) Heart - (OCS DCD Heart Trial). J Heart Lung Transplant, 2022, 41: S72.
72.	Schroder JN, Scheuer S, Catarino P, et al. The American Association for Thoracic Surgery 2023 Expert Consensus Document: Adult cardiac transplantation utilizing donors after circulatory death. J Thorac Cardiovasc Surg, 2023, 166(3): 856-869.
73.	中国医师协会器官移植医师分会, 中华医学会器官移植学分会, 中华医学会外科学分会移植学组, 等. 中国心脏死亡捐献器官评估与应用专家共识 (2022版). 中华移植杂志(电子版), 2022, 16(6): 321-328.Chinese College of Transplant Doctors, Chinese Society of Organ Transplantation, Section of Organ Trans-plantation Chinese Society of Surgery, et al. Expert consensus on evaluation and application of organs donated after cardiac death in China (2022 edition). Chin J Transpl (Electronic Edition), 2022, 16(6): 321-328.
74.	Porrett PM, Orandi BJ, Kumar V, et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am J Transplant, 2022, 22(4): 1037-1053.
75.	Griffith BP, Goerlich CE, Singh AK, et al. Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med, 2022, 387(1): 35-44.
76.	Denner J, Längin M, Reichart B, et al. Impact of porcine cytomegalovirus on long-term orthotopic cardiac xenotransplant survival. Sci Rep, 2020, 10(1): 17531.
77.	NYU Langone Health. Successful heart xenotransplant experiments at NYU langone set protocol for pig-to-human organ transplants. https://nyulangone.org/news/successful-heart-xenotransplant-experiments-nyu-langone-set-protocol-pig- human-organ-transplants (2022).
78.	Kittleson MM, Sharma K, Brennan DC, et al. Dual-organ transplantation: Indications, evaluation, and outcomes for heart-kidney and heart-liver transplantation: A scientific statement from the American Heart Association. Circulation, 2023, 148(7): 622-636.
79.	Schmitto JD, Shaw S, Garbade J, et al. Fully magnetically centrifugal left ventricular assist device and long-term outcomes: The ELEVATE registry. Eur Heart J, 2024, 45(8): 613-625.
80.	中国心室辅助装置专家共识委员会. 中国左心室辅助装置候选者术前评估与管理专家共识(2023年). 中国循环杂志, 2023, 38(8): 799-814.Chinese Expert Consensus Committee on Ventricular Assist Devices. 2023 expert consensus on pre-procedure evaluation and management of eligible patients for left ventricular assist devices. Chin Circ J, 2023, 38(8): 799-814.
81.	《左心室辅助装置植入全程管理专家共识(2023年)》工作组, 四川省医疗卫生与健康促进会心脏重症与辅助支持专业委员会, 中国超声心动图学会, 等. 左心室辅助装置植入全程管理专家共识(2023年). 实用医院临床杂志, 2024, 21(1): 43-55.Workgroup of Expert Consensus on the Whole-Process Management of Left Ventricular Assist Device Implantation (2023), Cardiac Critical Care and Mechanical Circulation Support Committee of Sichuan Medical and Health Care Promotion Institute, Chinese Society of Echocardiography. Expert consensus on the whole-process management of left ventricular assist device implantation 2023. Pract J Clin Med, 2024, 21(1): 43-55.
82.	Trachtenberg B, Cowger J, Jennings DL, et al. HFSA expert consensus statement on the medical management of patients on durable mechanical circulatory support. J Card Fail, 2023, 29(4): 479-502.
83.	Mullens W, Dauw J, Gustafsson F, et al. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). Eur J Heart Fail, 2024, 26(2): 483-501.
84.	Tedford RJ, Leacche M, Lorts A, et al. Durable mechanical circulatory support: JACC scientific statement. J Am Coll Cardiol, 2023, 82(14): 1464-1481.
85.	Bernhardt AM, Copeland H, Deswal A, et al. The International Society for Heart and Lung Transplantation/Heart Failure Society of America guideline on acute mechanical circulatory support. J Heart Lung Transplant, 2023, 42(4): e1-e64.
86.	Adamopoulos S, Bonios M, Ben Gal T, et al. Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 2024.
87.	Saeed D, Feldman D, Banayosy AE, et al. The 2023 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: A 10-year update. J Heart Lung Transplant, 2023, 42(7): e1-e222.
88.	Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2023, 148(9): e9-e119.
89.	Bakaeen FG, Ruel M, Calhoon JH, et al. STS/AATS-endorsed rebuttal to 2023 ACC/AHA chronic coronary disease guideline: A missed opportunity to present accurate and comprehensive revascularization recommendations. J Thorac Cardiovasc Surg, 2023, 166(4): 1115-1118.
90.	Byrne RA, Fremes S, Capodanno D, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur J Cardiothorac Surg, 2023, 64(2): ezad286.
91.	Gaudino M, Bakaeen FG, Sandner S, et al. Expert systematic review on the choice of conduits for coronary artery bypass grafting: Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and The Society of Thoracic Surgeons (STS). J Thorac Cardiovasc Surg, 2023, 166(4): 1099-1114.
92.	Gaba P, Christiansen EH, Nielsen PH, et al. Percutaneous coronary intervention vs coronary artery bypass graft surgery for left main disease in patients with and without acute coronary syndromes: A pooled analysis of 4 randomized clinical trials. JAMA Cardiol, 2023, 8(7): 631-639.
93.	Persson J, Yan J, Angerås O, et al. PCI or CABG for left main coronary artery disease: The SWEDEHEART registry. Eur Heart J, 2023, 44(30): 2833-2842.
94.	Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery. N Engl J Med, 2022, 386(2): 128-137.
95.	Zimmermann FM, Ding VY, Pijls NHJ, et al. Fractional flow reserve-guided PCI or coronary bypass surgery for 3-vessel coronary artery disease: 3-year follow-up of the FAME 3 trial. Circulation, 2023, 148(12): 950-958.
96.	Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med, 2022, 387(15): 1351-1360.
97.	Iribarne A, DiScipio AW, Leavitt BJ, et al. Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world surgical treatment for ischemic heart failure trial population. J Thorac Cardiovasc Surg, 2018, 156(4): 1410-1421.
98.	Buxton BF, Hayward PA, Raman J, et al. Long-term results of the RAPCO trials. Circulation, 2020, 142(14): 1330-1338.
99.	Shih E, Squiers JJ, Banwait JK, et al. Vein graft use and long-term survival following coronary bypass grafting. J Am Coll Cardiol, 2023, 81(8): 713-725.
100.	Borlaug BA, Schaff HV, Asirvatham SJ, et al. Surgical pericardiotomy to treat heart failure with preserved ejection fraction: A first clinical study. Eur Heart J, 2023, 44(44): 4719-4721.
101.	Hamid N, Jorde UP, Reisman M, et al. Transcatheter left ventricular restoration in patients with heart failure. J Card Fail, 2023, 29(7): 1046-1055.
102.	Sideris K, Liori S. Evaluating the role of interatrial shunt devices in heart failure management: Insights from the RELIEVE-HF trial. Heart Fail Rev, 2024, 29(5): 909-912.
103.	Isselbacher EM, Preventza O, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2022, 80(24): e223-e393.
104.	Czerny M, Grabenwöger M, Berger T, et al. EACTS/STS guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Eur J Cardiothorac Surg, 2024, 65(2): ezad426.
105.	Wu J, Zafar MA, Liu Y, et al. Fate of the unoperated ascending thoracic aortic aneurysm: Three-decade experience from the aortic institute at Yale University. Eur Heart J, 2023, 44(43): 4579-4588.
106.	Xiao M, Wu J, Chen D, et al. Ascending aortic volume: A feasible indicator for ascending aortic aneurysm elective surgery? Acta Biomater, 2023, 167: 100-108.
107.	Rylski B, Schilling O, Czerny M. Acute aortic dissection: Evidence, uncertainties, and future therapies. Eur Heart J, 2023, 44(10): 813-821.
108.	Nitta T, Wai JWW, Lee SH, et al. 2023 APHRS expert consensus statements on surgery for AF. J Arrhythm, 2023, 39(6): 841-852.
109.	Bisleri G, Pandey AK, Verma S, et al. Combined minimally invasive surgical and percutaneous catheter ablation of atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol, 2023, 81(6): 606-619.

1. Lee G, Chikwe J, Milojevic M, et al. ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Eur Heart J, 2023, 44(10): 796-812.
2. Blankenberg S, Seiffert M, Vonthein R, et al. Transcatheter or surgical treatment of aortic-valve stenosis. N Engl J Med, 2024, 390(17): 1572-1583.
3. Thyregod HGH, Jørgensen TH, Ihlemann N, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J, 2024, 45(13): 1116-1124.
4. Elbasha K, Kaur J, Abdelghani M, et al. Ten-year durability, hemodynamic performance, and clinical outcomes after transcatheter aortic valve implantation using a self-expanding device. Cardiol Ther, 2024, 13(3): 529-540.
5. Tarantini G, Dvir D, Tang GHL. Transcatheter aortic valve implantation in degenerated surgical aortic valves. EuroIntervention, 2021, 17(9): 709-719.
6. Mehta CK, Liu TX, Bonnell L, et al. Age-stratified surgical aortic valve replacement for aortic stenosis. Ann Thorac Surg, 2024, 118(2): 430-438.
7. Sharma T, Krishnan AM, Lahoud R, et al. National trends in TAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol, 2022, 80(21): 2054-2056.
8. Basman C, Pirelli L, Singh VP, et al. Lifetime management for aortic stenosis: Planning for future therapies. J Cardiol, 2022, 80(3): 185-189.
9. Russo G, Tang GHL, Sangiorgi G, et al. Lifetime management of aortic stenosis: Transcatheter versus surgical treatment for young and low-risk patients. Circ Cardiovasc Interv, 2022, 15(11): 915-927.
10. Baman JR, Medhekar AN, Malaisrie SC, et al. Management challenges in patients younger than 65 years with severe aortic valve disease: A review. JAMA Cardiol, 2023, 8(3): 281-289.
11. Mylonas KS, Angouras DC. Bioprosthetic valves for lifetime management of aortic stenosis: Pearls and pitfalls. J Clin Med, 2023, 12(22): 7063.
12. Geuens L, Van Hoof L, Van De Bruaene A, et al. Aortic valve replacement in non-elderly: The gap between reality, guidelines and evidence. Eur J Cardiothorac Surg, 2023, 64(5): ezad318.
13. Jubran A, Patel RV, Sathananthan J, et al. Lifetime management of patients with severe aortic stenosis in the era of transcatheter aortic valve replacement. Can J Cardiol, 2024, 40(2): 210-217.
14. Matsushita K, Morel O, Ohlmann P. Contemporary issues and lifetime management in patients underwent transcatheter aortic valve replacement. Cardiovasc Interv Ther, 2023, 38(3): 275-286.
15. Medranda GA, Soria Jimenez CE, Torguson R, et al. Lifetime management of patients with symptomatic severe aortic stenosis: A computed tomography simulation study. EuroIntervention, 2022, 18(5): e407-e416.
16. De Backer O, Søndergaard L. Discussing lifetime management of patients with severe aortic valve stenosis should be standard at heart team meetings. JACC Cardiovasc Interv, 2022, 15(7): 709-711.
17. Sá MP, Ramlawi B, Sicouri S, et al. Lifetime management of aortic valve disease: Aligning surgical and transcatheter armamentarium to set the tone for the present and the future. J Card Surg, 2022, 37(1): 205-213.
18. Reul RM, Nissen AP, Tom SK, et al. Incorporating redo-TAVR feasibility into lifelong aortic valve management. Circ Cardiovasc Interv, 2023, 16(11): e013571.
19. Prendergast BP, Patterson T. New paradigms for the sequential treatment of severe aortic stenosis: Imaging-guided selection of the first intervention paves the way for lifetime management. EuroIntervention, 2022, 18(5): e357-e359.
20. Tully A, Tom S, Crepy D'Orleans C, et al. Advancing transcatheter aortic valve replacement to the frontiers of lifetime valve management: Deliberations from the OBSERVANTⅡ trial. Circ Cardiovasc Interv, 2022, 15(12): e012607.
21. Sharaf OM, Beaver TM. Aortic valve 2024: Which valve for which patient? J Thorac Cardiovasc Surg, 2024: S0022-5223.
22. Leone PP, Regazzoli D, Pagnesi M, et al. Implantation of contemporary transcatheter aortic valves in small aortic annuli: The international multicentre TAVI-SMALL 2 registry. EuroIntervention, 2023, 19(3): 256-266.
23. Rao V, Linick JA, Reardon MJ, et al. Early and late effects of aortic root enlargement: Results from the pericardial surgical aortic valve replacement pivotal trial: A multicenter, prospective clinical trial. JTCVS Open, 2022, 13: 54-74.
24. Yang B. Aortic annular enlargement with Y-incision/rectangular patch. Ann Cardiothorac Surg, 2024, 13(3): 294-302.
25. Sá MPBO, Van den Eynde J, Simonato M, et al. Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement: An updated meta-analysis. JACC Cardiovasc Interv, 2021, 14(2): 211-220.
26. Woitek FJ, Stachel G, Kiefer P, et al. Treatment of failed aortic bioprostheses: An evaluation of conventional redo surgery and transfemoral transcatheter aortic valve-in-valve implantation. Int J Cardiol, 2020, 300: 80-86.
27. Bagga S, Chhatriwalla AK. Updates on bioprosthetic valve fracture. Expert Rev Cardiovasc Ther, 2023, 21(6): 409-422.
28. Ochiai T, Oakley L, Sekhon N, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2020, 13(22): 2617-2627.
29. Kitamura M, Wilde J, Dumpies O, et al. Risk assessment of coronary obstruction during transcatheter aortic valve replacement: Insights from post-BASILICA computed tomography. JACC Cardiovasc Interv, 2022, 15(5): 496-507.
30. Babaliaros VC, Gleason PT, Xie JX, et al. Toward transcatheter leaflet removal with the CATHEDRAL procedure: CATHeter Electrosurgical Debulking and RemovAL. JACC Cardiovasc Interv, 2022, 15(16): 1678-1680.
31. Vilalta V, Asmarats L, Ferreira-Neto AN, et al. Incidence, clinical characteristics, and impact of acute coronary syndrome following transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2018, 11(24): 2523-2533.
32. Barbanti M, Costa G, Picci A, et al. Coronary cannulation after transcatheter aortic valve replacement: The RE-ACCESS study. JACC Cardiovasc Interv, 2020, 13(21): 2542-2555.
33. Tang GHL, Zaid S. Commissural (mis)alignment in TAVR and hemodynamic impact: More questions raised than answered. JACC Cardiovasc Interv, 2022, 15(11): 1137-1139.
34. Giuliani C, Zanuttini A, Salaun E, et al. Subclinical valve leaflet thrombosis following bioprosthetic aortic valve replacement. Curr Opin Cardiol, 2024, 39(5): 457-464.
35. Mauri V, Körber MI, Kuhn E, et al. Prognosis of persistent mitral regurgitation in patients undergoing transcatheter aortic valve replacement. Clin Res Cardiol, 2020, 109(10): 1261-1270.
36. Kang JJ, Fialka NM, El-Andari R, et al. Surgical vs transcatheter aortic valve replacement in bicuspid aortic valve stenosis: A systematic review and meta-analysis. Trends Cardiovasc Med, 2024, 34(5): 304-313.
37. Sá MP, Van den Eynde J, Jacquemyn X, et al. Long-term outcomes of Ross procedure versus mechanical aortic valve replacement: Meta-analysis of reconstructed time-to-event data. Trends Cardiovasc Med, 2024, 34(1): 29-36.
38. Shih E, Ryan WH, Squiers JJ, et al. Outcomes of the Ross procedure in patients older versus younger than 50 years old. Eur J Cardiothorac Surg, 2023, 64(4): ezad260.
39. Pollari F, Mamdooh H, Hitzl W, et al. Ten years' experience with the sutureless aortic valve replacement: Incidence and predictors for survival and valve durability at follow-up. Eur J Cardiothorac Surg, 2023, 63(2): ezac572.
40. Concistrè G, Bianchi G, Margaryan R, et al. Ten-year experience with sutureless Perceval bioprosthesis: Single-centre analysis in 1157 implants. J Cardiovasc Med (Hagerstown), 2023, 24(8): 506-513.
41. Lamberigts M, Sarrazin B, Szecel D, et al. 15 years of experience with sutureless AVR: Long-term outcome in 1135 patients. USA, Massachusetts: HVS 2024 annual meeting.
42. Bernard J, Georges G, Hecht S, et al. Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve: A retrospective comparison to the Magna Ease. Interdiscip Cardiovasc Thorac Surg, 2023, 37(1): ivad117.
43. Bavaria JE, Griffith B, Heimansohn DA, et al. Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue. Ann Thorac Surg, 2023, 115(6): 1429-1436.
44. Bartus K, Bavaria JE, Thourani VH, et al. Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses. J Comp Eff Res, 2023, 12(3): e220180.
45. Sef D, Thet MS, Klokocovnik T, et al. Early and mid-term outcomes after aortic valve replacement using a novel tissue bioprosthesis: A systematic review. Eur J Cardiothorac Surg, 2024, 65(2): ezae045.
46. Kereiakes DJ, Answini GA, Yakubov SJ, et al. Preliminary evaluation of a novel polymeric valve following surgical implantation for symptomatic aortic valve disease. JACC Cardiovasc Interv, 2021, 14(24): 2754-2756.
47. Ge JB. Innovations in structural heart diseases from China. USA, California: TCT, 2023.
48. Carrel T, Vogt PR, Obrist D, et al. Evolving technology: The TRIFLO tri-leaflet mechanical valve without oral anticoagulation: A potential major innovation in valve surgery. Front Cardiovasc Med, 2023, 10: 1220633.
49. Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: A report from the STS/ACC TVT Registry. Ann Thorac Surg, 2022, 113(1): 337-365.
50. Chikwe J, Chen Q, Bowdish ME, et al. Surgery and transcatheter intervention for degenerative mitral regurgitation in the United States. J Thorac Cardiovasc Surg, 2024.
51. Xu X, Liu H, Gu J, et al. Valve-in-valve/valve-in-ring transcatheter mitral valve implantation vs. redo surgical mitral valve replacement for patients with failed bioprosthetic valves or annuloplasty rings: A systematic review and meta-analysis. Heliyon, 2023, 9(5): e16078.
52. Ueyama HA, Miyamoto Y, Watanabe A, et al. Cardiac reoperation or transcatheter mitral valve replacement for patients with failed mitral prostheses. J Am Coll Cardiol, 2024, 83(2): 317-330.
53. Simard T, Lloyd J, Crestanello J, et al. Five-year outcomes of transcatheter mitral valve implantation and redo surgery for mitral prosthesis degeneration. Catheter Cardiovasc Interv, 2022, 99(5): 1659-1665.
54. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults. Am J Med, 2004, 116(1): 14-18.
55. Fang J, Liu Y, Zhu Y, et al. First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 2023, 82(7): 575-586.
56. Li J, Wei X. Transapical beating-heart septal myectomy for hypertrophic cardiomyopathy with latent obstruction. Eur J Cardiothorac Surg, 2024, 65(1): ezad425.
57. Schaff HV, Cui H. Septal myectomy: An evolving therapy for obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol, 2023, 82(7): 587-589.
58. Quintana E, Schaff HV, Stradiņš P, et al. Beating heart transapical septal myectomy—A less invasive septal reduction option for hypertrophic cardiomyopathy. Eur J Cardiothorac Surg, 2024, 65(1): ezae003.
59. Fang J, Liu Y, Wan S, et al. Reply: Potential expanded applications of minimally invasive cardiac myectomy. J Am Coll Cardiol, 2023, 82(24): e237.
60. Pai RG. Potential Expanded applications of minimally invasive cardiac myectomy. J Am Coll Cardiol, 2023, 82(24): e235.
61. Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2020 annual data report: Heart. Am J Transplant, 2022, 22 Suppl 2: 350-437.
62. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report—2019; focus theme: Donor and recipient size matchJ Heart Lung Transplant, 2019, 38(10): 1056-1066.
63. Jou S, Mendez SR, Feinman J, et al. Heart transplantation: Advances in expanding the donor pool and xenotransplantation. Nat Rev Cardiol, 2024, 21(1): 25-36.
64. Crespo-Leiro MG, Costanzo MR, Gustafsson F, et al. Heart transplantation: Focus on donor recovery strategies, left ventricular assist devices, and novel therapies. Eur Heart J, 2022, 43(23): 2237-2246.
65. Kilic A, Hickey G, Mathier M, et al. Outcomes of adult heart transplantation using hepatitis C-positive donors. J Am Heart Assoc, 2020, 9(2): e014495.
66. Aslam S, Grossi P, Schlendorf KH, et al. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant, 2020, 39(5): 418-432.
67. Villegas-Galaviz J, Anderson E, Guglin M. Clinical outcomes of heart transplantation using hepatitis C-viremic donors: A systematic review with meta-analysis. J Heart Lung Transplant, 2022, 41(4): 538-549.
68. Gidea CG, Narula N, Reyentovich A, et al. Increased early acute cellular rejection events in hepatitis C-positive heart transplantation. J Heart Lung Transplant, 2020, 39(11): 1199-1207.
69. Madan S, Saeed O, Forest SJ, et al. Feasibility and potential impact of heart transplantation from adult donors after circulatory death. J Am Coll Cardiol, 2022, 79(2): 148-162.
70. Louca J, Öchsner M, Shah A, et al. The international experience of in-situ recovery of the DCD heart: A multicentre retrospective observational study. EClinicalMedicine, 2023, 58: 101887.
71. Schroder J, Shah A, Pretorius V, et al. Expanding heart transplants from donors after Circulatory Death (DCD)—Results of the first randomized controlled trial using the Organ Care System (OCS™) Heart - (OCS DCD Heart Trial). J Heart Lung Transplant, 2022, 41: S72.
72. Schroder JN, Scheuer S, Catarino P, et al. The American Association for Thoracic Surgery 2023 Expert Consensus Document: Adult cardiac transplantation utilizing donors after circulatory death. J Thorac Cardiovasc Surg, 2023, 166(3): 856-869.
73. 中国医师协会器官移植医师分会, 中华医学会器官移植学分会, 中华医学会外科学分会移植学组, 等. 中国心脏死亡捐献器官评估与应用专家共识 (2022版). 中华移植杂志(电子版), 2022, 16(6): 321-328.Chinese College of Transplant Doctors, Chinese Society of Organ Transplantation, Section of Organ Trans-plantation Chinese Society of Surgery, et al. Expert consensus on evaluation and application of organs donated after cardiac death in China (2022 edition). Chin J Transpl (Electronic Edition), 2022, 16(6): 321-328.
74. Porrett PM, Orandi BJ, Kumar V, et al. First clinical-grade porcine kidney xenotransplant using a human decedent model. Am J Transplant, 2022, 22(4): 1037-1053.
75. Griffith BP, Goerlich CE, Singh AK, et al. Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med, 2022, 387(1): 35-44.
76. Denner J, Längin M, Reichart B, et al. Impact of porcine cytomegalovirus on long-term orthotopic cardiac xenotransplant survival. Sci Rep, 2020, 10(1): 17531.
77. NYU Langone Health. Successful heart xenotransplant experiments at NYU langone set protocol for pig-to-human organ transplants. https://nyulangone.org/news/successful-heart-xenotransplant-experiments-nyu-langone-set-protocol-pig- human-organ-transplants (2022).
78. Kittleson MM, Sharma K, Brennan DC, et al. Dual-organ transplantation: Indications, evaluation, and outcomes for heart-kidney and heart-liver transplantation: A scientific statement from the American Heart Association. Circulation, 2023, 148(7): 622-636.
79. Schmitto JD, Shaw S, Garbade J, et al. Fully magnetically centrifugal left ventricular assist device and long-term outcomes: The ELEVATE registry. Eur Heart J, 2024, 45(8): 613-625.
80. 中国心室辅助装置专家共识委员会. 中国左心室辅助装置候选者术前评估与管理专家共识(2023年). 中国循环杂志, 2023, 38(8): 799-814.Chinese Expert Consensus Committee on Ventricular Assist Devices. 2023 expert consensus on pre-procedure evaluation and management of eligible patients for left ventricular assist devices. Chin Circ J, 2023, 38(8): 799-814.
81. 《左心室辅助装置植入全程管理专家共识(2023年)》工作组, 四川省医疗卫生与健康促进会心脏重症与辅助支持专业委员会, 中国超声心动图学会, 等. 左心室辅助装置植入全程管理专家共识(2023年). 实用医院临床杂志, 2024, 21(1): 43-55.Workgroup of Expert Consensus on the Whole-Process Management of Left Ventricular Assist Device Implantation (2023), Cardiac Critical Care and Mechanical Circulation Support Committee of Sichuan Medical and Health Care Promotion Institute, Chinese Society of Echocardiography. Expert consensus on the whole-process management of left ventricular assist device implantation 2023. Pract J Clin Med, 2024, 21(1): 43-55.
82. Trachtenberg B, Cowger J, Jennings DL, et al. HFSA expert consensus statement on the medical management of patients on durable mechanical circulatory support. J Card Fail, 2023, 29(4): 479-502.
83. Mullens W, Dauw J, Gustafsson F, et al. Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). Eur J Heart Fail, 2024, 26(2): 483-501.
84. Tedford RJ, Leacche M, Lorts A, et al. Durable mechanical circulatory support: JACC scientific statement. J Am Coll Cardiol, 2023, 82(14): 1464-1481.
85. Bernhardt AM, Copeland H, Deswal A, et al. The International Society for Heart and Lung Transplantation/Heart Failure Society of America guideline on acute mechanical circulatory support. J Heart Lung Transplant, 2023, 42(4): e1-e64.
86. Adamopoulos S, Bonios M, Ben Gal T, et al. Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 2024.
87. Saeed D, Feldman D, Banayosy AE, et al. The 2023 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: A 10-year update. J Heart Lung Transplant, 2023, 42(7): e1-e222.
88. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2023, 148(9): e9-e119.
89. Bakaeen FG, Ruel M, Calhoon JH, et al. STS/AATS-endorsed rebuttal to 2023 ACC/AHA chronic coronary disease guideline: A missed opportunity to present accurate and comprehensive revascularization recommendations. J Thorac Cardiovasc Surg, 2023, 166(4): 1115-1118.
90. Byrne RA, Fremes S, Capodanno D, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG. Eur J Cardiothorac Surg, 2023, 64(2): ezad286.
91. Gaudino M, Bakaeen FG, Sandner S, et al. Expert systematic review on the choice of conduits for coronary artery bypass grafting: Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and The Society of Thoracic Surgeons (STS). J Thorac Cardiovasc Surg, 2023, 166(4): 1099-1114.
92. Gaba P, Christiansen EH, Nielsen PH, et al. Percutaneous coronary intervention vs coronary artery bypass graft surgery for left main disease in patients with and without acute coronary syndromes: A pooled analysis of 4 randomized clinical trials. JAMA Cardiol, 2023, 8(7): 631-639.
93. Persson J, Yan J, Angerås O, et al. PCI or CABG for left main coronary artery disease: The SWEDEHEART registry. Eur Heart J, 2023, 44(30): 2833-2842.
94. Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery. N Engl J Med, 2022, 386(2): 128-137.
95. Zimmermann FM, Ding VY, Pijls NHJ, et al. Fractional flow reserve-guided PCI or coronary bypass surgery for 3-vessel coronary artery disease: 3-year follow-up of the FAME 3 trial. Circulation, 2023, 148(12): 950-958.
96. Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med, 2022, 387(15): 1351-1360.
97. Iribarne A, DiScipio AW, Leavitt BJ, et al. Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world surgical treatment for ischemic heart failure trial population. J Thorac Cardiovasc Surg, 2018, 156(4): 1410-1421.
98. Buxton BF, Hayward PA, Raman J, et al. Long-term results of the RAPCO trials. Circulation, 2020, 142(14): 1330-1338.
99. Shih E, Squiers JJ, Banwait JK, et al. Vein graft use and long-term survival following coronary bypass grafting. J Am Coll Cardiol, 2023, 81(8): 713-725.
100. Borlaug BA, Schaff HV, Asirvatham SJ, et al. Surgical pericardiotomy to treat heart failure with preserved ejection fraction: A first clinical study. Eur Heart J, 2023, 44(44): 4719-4721.
101. Hamid N, Jorde UP, Reisman M, et al. Transcatheter left ventricular restoration in patients with heart failure. J Card Fail, 2023, 29(7): 1046-1055.
102. Sideris K, Liori S. Evaluating the role of interatrial shunt devices in heart failure management: Insights from the RELIEVE-HF trial. Heart Fail Rev, 2024, 29(5): 909-912.
103. Isselbacher EM, Preventza O, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2022, 80(24): e223-e393.
104. Czerny M, Grabenwöger M, Berger T, et al. EACTS/STS guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Eur J Cardiothorac Surg, 2024, 65(2): ezad426.
105. Wu J, Zafar MA, Liu Y, et al. Fate of the unoperated ascending thoracic aortic aneurysm: Three-decade experience from the aortic institute at Yale University. Eur Heart J, 2023, 44(43): 4579-4588.
106. Xiao M, Wu J, Chen D, et al. Ascending aortic volume: A feasible indicator for ascending aortic aneurysm elective surgery? Acta Biomater, 2023, 167: 100-108.
107. Rylski B, Schilling O, Czerny M. Acute aortic dissection: Evidence, uncertainties, and future therapies. Eur Heart J, 2023, 44(10): 813-821.
108. Nitta T, Wai JWW, Lee SH, et al. 2023 APHRS expert consensus statements on surgery for AF. J Arrhythm, 2023, 39(6): 841-852.
109. Bisleri G, Pandey AK, Verma S, et al. Combined minimally invasive surgical and percutaneous catheter ablation of atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol, 2023, 81(6): 606-619.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Technological development frontier and future trend of cardiovascular surgery

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content